David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)

Fol­low­ing the gov­ern­men­t's lead, Lil­ly caps out-of-pock­et costs for in­sulin at $35 per month

Eli Lil­ly is look­ing to get ahead of any more fed­er­al ac­tion on in­sulin prices, an­nounc­ing to­day that it will not on­ly slash its most com­mon­ly used in­sulin by 70%, but cap out-of-pock­et costs for those on com­mer­cial in­sur­ance at $35 per month — just as the fed­er­al gov­ern­ment re­cent­ly did for those in­sured by Medicare.

The move to again slash the cost of in­sulin — back in 2019, Lil­ly cut the list price of Hu­ma­log by 50% — comes as ra­tioning of the life-sav­ing shot has led to deaths for some di­a­bet­ics who could not af­ford their in­jec­tions, even as Con­gress is work­ing on an­oth­er push to cap out-of-pock­et costs for di­a­bet­ics af­ter Sen­ate Re­pub­li­cans shot down the idea last Au­gust.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.